Overactive bladder
Conditions
Interventions
None listed
Sponsors
Clinical Research Support Center Kyushu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who are regarded as overactive bladder at the start of dosing imidafenacin 2)Patients who have the follow criteria even after administering imidafenacin for more than 4 weeks IPSS Q7(nocturia score) >=3 3)Aged >=20 years
Exclusion criteria
Exclusion criteria: 1)Patients with contraindications for imidafenacin 2)Patients who have current condition of severe difficulty of urination 3)Patients who have history of urinary retention 4)Patients with serious kidney dysfunction 5)Residual urine volume > 50 mL 6)Patients with cancer in bladder, cystoliths, urinary tract infection, recurrent urinary tract infection or interstitial cystitis 7)Patients with polyuria 8)Patients who have administered prohibited substances or done prohibited therapy in the 4 weeks prior to the start of study (excepting operations on urinary and sexual organs) 9)Patients who have been operated on the urinary or sexual organs in the 6 months prior to the start of study 10)Patients with unstable lower urinary tract symptoms 11)Any other patients who are regarded as unsuitable for this study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in IPSS Q7 (nocturia score) as change in nocturnal voids | — |
Countries
Japan
Contacts
Public ContactYasuyuki Suzuki
Tokyo Metropolitan Rehabilitation Hospital Department of Medical Care
Outcome results
None listed